Thomas Dörner Selected Research

Systemic Lupus Erythematosus (Libman-Sacks Disease)

7/2022	Phase 3, multicentre, randomised, placebo-controlled study evaluating the efficacy and safety of ustekinumab in patients with systemic lupus erythematosus.
5/2022	Mechanism of action of baricitinib and identification of biomarkers and key immune pathways in patients with active systemic lupus erythematosus.
4/2022	Biological impact of iberdomide in patients with active systemic lupus erythematosus.
1/2022	Plasmablast-like Phenotype Among Antigen-Experienced CXCR5-CD19low B Cells in Systemic Lupus Erythematosus.
1/2022	Phase 2 Trial of Iberdomide in Systemic Lupus Erythematosus.
1/2022	Baricitinib decreases anti-dsDNA in patients with systemic lupus erythematosus: results from a phase II double-blind, randomized, placebo-controlled trial.
11/2021	Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus.
11/2021	2021 DORIS definition of remission in SLE: final recommendations from an international task force.
11/2021	Immune checkpoints and the multiple faces of B cells in systemic lupus erythematosus.
1/2021	Toll-like receptor signalling in B cells during systemic lupus erythematosus.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Thomas Dörner Research Topics

Disease

48	Rheumatoid Arthritis 01/2022 - 10/2002
47	Systemic Lupus Erythematosus (Libman-Sacks Disease) 07/2022 - 10/2002
26	Autoimmune Diseases (Autoimmune Disease) 01/2022 - 10/2002
15	Rheumatic Diseases (Rheumatism) 01/2022 - 08/2003
12	Infections 01/2022 - 05/2008
9	Vasculitis (Vasculitides) 01/2022 - 05/2004
7	COVID-19 01/2022 - 01/2020
7	Antiphospholipid Syndrome (Antiphospholipid Antibody Syndrome) 04/2020 - 05/2011
6	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2012 - 05/2006
5	Arthritis (Polyarthritis) 06/2022 - 05/2009
5	Inflammation (Inflammations) 05/2022 - 01/2005
5	Fatigue 01/2021 - 06/2011
5	Multiple Sclerosis 01/2016 - 05/2011
4	Necrosis 05/2022 - 01/2007
4	Spontaneous Abortion (Miscarriage) 04/2020 - 12/2009
3	Lupus Nephritis 01/2019 - 11/2012
3	Habitual Abortion (Recurrent Miscarriage) 03/2018 - 12/2009
3	Idiopathic Thrombocytopenic Purpura (Thrombocytopenic Purpura, Autoimmune) 12/2012 - 01/2007
3	Venous Thromboembolism 12/2012 - 02/2005
3	Tetanus 07/2010 - 03/2006
2	Synovitis 06/2022 - 05/2004
2	Joint Diseases (Joint Disease) 06/2022 - 05/2006
2	Fever (Fevers) 01/2022 - 01/2019
2	Tertiary Lymphoid Structures 11/2021 - 07/2010
2	Dry Eye Syndromes (Dry Eye Syndrome) 01/2021 - 01/2019
2	Alopecia (Baldness) 12/2020 - 01/2019
2	Virus Diseases (Viral Diseases) 01/2020 - 09/2007
2	Pregnancy Complications 10/2019 - 01/2018
2	Thrombosis (Thrombus) 10/2019 - 01/2018
2	Autoimmune Hemolytic Anemia (Cold Agglutinin Disease) 01/2019 - 11/2002
2	Pain (Aches) 01/2019 - 06/2011
2	Cytopenia 01/2019 - 08/2009
2	Thrombophilia 03/2018 - 12/2009
2	Congenital heart block 08/2017 - 05/2002
2	Myositis (Idiopathic Inflammatory Myopathies) 03/2016 - 06/2008
2	Pemphigus (Pemphigus Vulgaris) 10/2012 - 05/2011
2	Diphtheria 07/2010 - 03/2009
2	Neoplasms (Cancer) 10/2007 - 09/2007
2	Hypergammaglobulinemia (Hyperimmunoglobulinemia) 01/2007 - 10/2004

Drug/Important Bio-Agent (IBA)

25	Rituximab (Mabthera)FDA Link 01/2022 - 01/2005
18	AutoantibodiesIBA 06/2022 - 05/2003
14	CytokinesIBA 01/2022 - 05/2004
10	AntibodiesIBA 01/2022 - 05/2004
9	AntigensIBA 01/2022 - 05/2002
7	Biomarkers (Surrogate Marker)IBA 05/2022 - 03/2010
7	epratuzumabIBA 01/2018 - 01/2006
6	Biological ProductsIBA 04/2022 - 05/2009
6	VaccinesIBA 01/2022 - 03/2006
5	Immunoglobulins (Immunoglobulin)IBA 08/2011 - 10/2004
4	DNA (Deoxyribonucleic Acid)IBA 05/2022 - 01/2019
4	baricitinibIBA 05/2022 - 01/2018
4	Antineutrophil Cytoplasmic Antibodies (ANCA)IBA 01/2022 - 05/2011
4	Antimalarials (Antimalarial Agents)IBA 11/2021 - 03/2017
4	Immunoglobulin G (IgG)IBA 01/2021 - 03/2009
4	Antiphospholipid AntibodiesIBA 12/2020 - 07/2011
4	Hydroxychloroquine (Plaquenil)FDA LinkGeneric 01/2020 - 01/2018
4	Heparin (Liquaemin)FDA LinkGeneric 10/2019 - 12/2009
4	Biosimilar PharmaceuticalsIBA 01/2018 - 03/2013
4	Monoclonal AntibodiesIBA 01/2015 - 01/2010
3	Interleukin-6 (Interleukin 6)IBA 05/2022 - 05/2011
3	Antiviral Agents (Antivirals)IBA 01/2022 - 09/2007
3	Prostaglandins AIBA 11/2021 - 06/2011
3	Antinuclear AntibodiesIBA 01/2021 - 11/2014
3	Toll-Like Receptors (Toll-Like Receptor)IBA 01/2021 - 05/2004
3	tocilizumab (atlizumab)FDA Link 11/2019 - 05/2011
3	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 10/2019 - 05/2011
3	Immunoglobulin M (IgM)IBA 03/2014 - 07/2010
3	AutoantigensIBA 12/2012 - 05/2003
3	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 08/2009 - 08/2003
3	Antigen-Antibody Complex (Immune Complex)IBA 01/2007 - 05/2004
2	ChemokinesIBA 05/2022 - 05/2004
2	Janus KinasesIBA 05/2022 - 01/2018
2	LigandsIBA 05/2022 - 01/2019
2	iberdomideIBA 04/2022 - 01/2022
2	InterferonsIBA 01/2022 - 01/2017
2	Sialic Acid Binding Ig-like Lectin 1IBA 01/2022 - 07/2015
2	ianalumabIBA 01/2022 - 01/2019
2	BNT162 VaccineIBA 01/2022 - 01/2021
2	COVID-19 VaccinesIBA 01/2022 - 01/2022
2	Transcription Factors (Transcription Factor)IBA 01/2022 - 03/2014
2	Interferon Type IIBA 01/2022 - 08/2017
2	Messenger RNA (mRNA)IBA 01/2022 - 01/2022
2	dapirolizumab pegolIBA 11/2021 - 11/2017
2	Prednisolone (Predate)FDA LinkGeneric 11/2021 - 10/2019
2	Syk KinaseIBA 01/2020 - 12/2014
2	Antirheumatic Agents (DMARD)IBA 11/2019 - 01/2015
2	Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)IBA 10/2019 - 12/2009
2	Vitamin K FDA Link 10/2019 - 10/2014
2	Therapeutic UsesIBA 01/2019 - 08/2003
2	Adrenal Cortex Hormones (Corticosteroids)IBA 03/2017 - 03/2016
2	Blood Coagulation Factors (Coagulation Factor)IBA 10/2014 - 12/2012
2	Proteasome Endopeptidase Complex (Proteasome)IBA 05/2013 - 10/2002
2	Inosine Triphosphate (ITP)IBA 12/2012 - 01/2007
2	Fibrinogen (Factor I)FDA Link 12/2012 - 07/2012
2	FibrinIBA 12/2012 - 07/2012
2	B-Cell Activating FactorIBA 01/2012 - 01/2007
2	HLA-DR Antigens (HLA-DR)IBA 12/2010 - 07/2010
2	Chemokine ReceptorsIBA 07/2010 - 01/2005
2	Peptide Hydrolases (Proteases)FDA Link 05/2006 - 02/2005

Therapy/Procedure

36	Therapeutics 05/2022 - 01/2005